United States Patent 11,833,130 (Tasimelteon) Claim Scope and U.S. Patent Landscape for Chronic Non-24 / Circadian Rhythm Advancement
US Patent 11,833,130 is a method-of-treatment patent focused on dosing tasimelteon for Non-24 (including “totally blind” Non-24) and on shifting/advancing circadian timing via a narrow oral dosing window relative to a patient’s desired bedtime. The claims are written to specific dose ranges (20 to 50 mg), a specific dosing clock-time window (about 0.5 to 1.5 hours before bedtime; dependent claims narrow to ~1 hour), and, in at least one claim, a clinical outcome metric tied to LQ-nTST and UQ-dTSD changes of at least 45 minutes each.
What do the claims of US 11,833,130 cover for tasimelteon Non-24 and circadian advancement?
Core claim structure. Claim 1 (and method-of-advancing claim 5) captures a dosing regimen rather than a composition. It covers a patient population and a dosing-time relationship to bedtime.
-
Claim 1 (totally blind Non-24; chronic treatment):
- Chronic treatment of Non-24 in a person who is totally blind
- Orally administer tasimelteon
- Dose: 20 to 50 mg
- Schedule: once daily
- Timing: about one-half hour to about one-and-one-half hours before the person’s desired bedtime
-
Claims 2 to 4 (dose and timing dependents):
- Claim 2: dose is 20 mg
- Claim 3: dose is 50 mg
- Claim 4: administered about one hour before desired bedtime
-
Claim 5 (circadian rhythm advancement method):
- Method of advancing a person’s circadian rhythm
- Tasimelteon orally
- Dose: 20 to 50 mg once daily
- Timing window: about 0.5 to 1.5 hours before desired bedtime
-
Claims 6 to 8 (dependents):
- Claim 6: 20 mg
- Claim 7: 50 mg
- Claim 8: ~1 hour before desired bedtime
-
Claim 9 (magnitude limitation):
- The dose “advances the person's circadian rhythm up to about five hours”
-
Claim 10 (clinical endpoint-based Non-24 method):
- Treat Non-24 by administering 20 mg tasimelteon once daily before target bedtime
- Over a dosing period sufficient to produce improvement in:
- Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST)
- Upper Quartile of Days of Daytime Total Sleep Time (UQ-dTSD)
- Improvement requires:
- LQ-nTST increase ≥ 45 minutes
- UQ-dTSD decrease ≥ 45 minutes
- relative to the patient’s pretreatment values
Claim-scope implications for infringement risk
- Infringement can hinge on “timing,” not only dose. The window “about one-half hour to about one-and-one-half hours before desired bedtime” is a material limitation. A regimen materially outside that timing window (even if dose is within 20 to 50 mg) is an avoidance path for design-around.
- Two patient lenses exist:
- Non-24 in totally blind persons (Claim 1)
- Circadian rhythm advancement in a person (Claim 5), which reads broader because it is not expressly limited to “totally blind” in the independent claim (though “person” may be interpreted by the context of use)
- Outcome-anchored claim 10 increases evidentiary burden. A party may still practice the dosing method but argue the claim is not met unless endpoint thresholds are satisfied in the “dosing period sufficient” to achieve them.
What is “desired bedtime” vs “target bedtime”?
The claims use “desired bedtime” (Claims 1, 4, 5, 8) and “target bedtime each day” (Claim 10). This matters for practice because the patient’s chosen bedtime (desired) could differ from a clinic’s prescribed target bedtime. The infringement analysis will typically focus on whether the timing relationship is measured against the patient’s desired/target bedtime under the asserted method.
How broad are the tasimelteon dosing windows (0.5 to 1.5 hours) and dose range (20 to 50 mg) in US 11,833,130?
Dose range breadth. The independent method claims use 20 to 50 mg once daily. That covers the endpoints of the dependent claims (20 mg and 50 mg) and also any intermediate dose within that range. From a claim-construction perspective, this is a broad dose spectrum for method-of-use coverage.
Timing window breadth. The timing limitation spans:
- earliest: about 0.5 hour before bedtime
- latest: about 1.5 hours before bedtime
The use of “about” provides some tolerance, but it still defines a bounded range.
Practical boundary risk.
- A generic or licensed entrant designing label language to move dosing outside 0.5–1.5 hours can reduce direct method-of-use infringement exposure.
- A provider instructing dosing outside the window, even if the product contains tasimelteon, is a key control lever.
Dependent narrowing to ~1 hour.
Claims 4, 8 are narrower and may be easiest for plaintiffs to prove because they align with typical “take 1 hour before bedtime” instructions used in some clinical regimens.
Which clinical endpoints does Claim 10 require and how do they constrain enforcement?
Claim 10 is a method for Non-24 with a specific tasimelteon regimen:
- 20 mg once daily
- “before target bedtime each day”
- duration “sufficient to produce” improvement in two quantified sleep metrics:
- LQ-nTST (increase ≥ 45 minutes)
- UQ-dTSD (decrease ≥ 45 minutes)
Why this matters legally.
- Claim 10 is “result-oriented” but phrased as a treatment method: the dosing period is sufficient to produce the specified improvements.
- Proving infringement can require clinical evidence linking the regimen to those endpoint thresholds, typically via a clinical study dataset, real-world evidence, or a trial mirroring the claimed regimen.
Commercial relevance.
- Labeling or prescribing patterns that produce materially different endpoint profiles can be argued not to meet Claim 10, even if the dosing-time and dose match.
What other US patents commonly surround tasimelteon for Non-24 and circadian disorders?
A complete landscape requires the full patent family data and citations for US 11,833,130. With only the asserted claim text provided, the following is the most accurate way to characterize the adjacent patent “buckets” that commonly surround tasimelteon and are likely to appear around this type of claim:
- Composition and formulation patents (e.g., oral solid dosing forms, stability, dosage unit design)
- Method-of-use patents (treatment of Non-24 in totally blind individuals; circadian rhythm shifting/advancement)
- Dosing regimen patents (timing relative to bedtime; dose-ranging; initiation titration rules)
- Outcome/biomarker or endpoint patents (sleep metrics such as total sleep time quartiles)
- Combination and patient-management patents (baseline assessment, light exposure adjuncts, behavioral components)
US 11,833,130 clearly falls into buckets 2, 3, and 5 (to the extent “desired bedtime/target bedtime” is a patient-management framing) and partly into bucket 4 via endpoint thresholds in Claim 10.
What claim elements create the strongest enforceability points for US 11,833,130?
Strongest enforceability elements (for plaintiffs).
- Patient context: “Non-24 in a person who is totally blind” in Claim 1
- Specific regimen: oral tasimelteon at 20–50 mg once daily
- Specific timing: “about 0.5 to about 1.5 hours before desired bedtime”
- Endpoint thresholds (Claim 10): LQ-nTST and UQ-dTSD quantified improvement requirements
Weakest enforceability elements (for defendants).
- “About” modifiers: “about one-half hour,” “about one-and-one-half hours,” “about one hour,” and “up to about five hours” create interpretive ranges that can either broaden (plaintiff-favorable) or invite “substantial difference” arguments (defendant-favorable), depending on the record and construction standard used.
- Broad “person” in Claim 5: if a defense argues “advancing circadian rhythm” outside a Non-24 context is not what the specification supports, the claim’s practical boundaries may narrow.
How does US 11,833,130 compare to typical tasimelteon method-of-use claim patterns?
Based on claim drafting form:
- Many circadian-disorder patents differentiate by:
- population (e.g., totally blind vs broader)
- direction (advance vs entrain)
- timing (how many hours before bedtime)
- US 11,833,130 is comparatively tight on timing and quantifies dose and, in Claim 10, quantifies outcomes.
This combination tends to make it less vulnerable than generic “treat Non-24 with tasimelteon once daily” claims, because timing and endpoints reduce the range of alleged infringing conduct.
What design-arounds can avoid the specific limits of US 11,833,130?
Design-around levers derived from claim limitations:
- Shift dosing time outside the window of “about 0.5 to about 1.5 hours before desired bedtime.”
- Use a dosing pattern not “once daily.” (Claims are once daily; different frequencies create a non-literal pathway.)
- Use different dose outside 20–50 mg for asserted independent claims (though Claim 10 is only 20 mg, so altering dose could bypass that claim too).
- Avoid the totally blind Non-24 framing by using the regimen only in populations and labeling contexts outside Claim 1’s “totally blind” constraint, though method-of-use claims can still be asserted if the actual treated population fits the claim.
- For Claim 10: attempt to avoid the claimed endpoint thresholds via different regimens or by not treating long enough to reach the specific LQ-nTST and UQ-dTSD changes. This is harder to police clinically and can be challenged with trial evidence.
What Orange Book status and Paragraph IV strategy issues are implicated by a method-of-use patent like US 11,833,130?
US 11,833,130 is a method-of-treatment claim set. The practical Orange Book and Hatch-Waxman implications depend on whether it is listed in the Orange Book for the approved tasimelteon product(s), and what the listed use code and patent scope cover.
For Paragraph IV challenges, the usual risk structure is:
- If US 11,833,130 is listed for the method-of-use that matches the label dosing instructions, a generic challenger must litigate for:
- invalidity, or
- non-infringement (often by asserting carve-outs from the claimed dosing timing/dose).
- If the listed use aligns tightly with the 0.5–1.5 hour window and 20–50 mg dosing, a generic company may face higher litigation risk unless it can credibly argue that its label does not encourage the claimed conduct.
Because this response is limited to the claim text provided and does not include Orange Book listing data, it does not supply a concrete Orange Book status summary.
Key Takeaways
- US 11,833,130 is a regimen-centric method-of-use patent for tasimelteon in Non-24 and for advancing circadian rhythm, with dose (20–50 mg once daily) and bedtime-relative timing (about 0.5 to 1.5 hours before desired bedtime) as the critical limiting features.
- Claims 1 and 5 anchor the core infringement theory: oral tasimelteon dosing in the specific time window.
- Claim 10 adds a second, more evidentiary constraint: 20 mg once daily administered “before target bedtime” with endpoint thresholds requiring at least +45 minutes in LQ-nTST and -45 minutes in UQ-dTSD.
- The strongest design-around path is timing: shift prescribing and label instructions outside the 0.5–1.5 hour window, or avoid clinical patterns that satisfy the endpoint thresholds in Claim 10.
FAQs
1) Does US 11,833,130 cover only totally blind Non-24 patients?
Claim 1 explicitly requires “Non-24 in a person who is totally blind.” Claim 5 is framed as “advancing a person’s circadian rhythm” and is not expressly limited to “totally blind” in the independent claim text shown.
2) What dose range is protected under the independent method claims?
Claims 1 and 5 require 20 mg to 50 mg once daily.
3) What timing relative to bedtime is protected?
Claims 1 and 5 require dosing about 0.5 hour to about 1.5 hours before the person’s desired bedtime.
4) What does Claim 10 require besides dosing time and dose?
Claim 10 requires a dosing period sufficient to achieve changes in LQ-nTST (+45 minutes) and UQ-dTSD (-45 minutes) relative to pretreatment values.
5) Can a 20 mg regimen outside the timing window still infringe?
If dosing time is materially outside “about one-half hour to about one-and-one-half hours before” desired bedtime, it does not fit the independent claim timing limitation as written.
References
- United States Patent 11,833,130. Claimed subject matter as provided in user prompt (claims 1-10).
